RE:Globe buy 90 centGustoes wrote: Phase I testing is already well advanced and generating encouraging early data," he said.Mr. Low called PDT TLD-1433, a bladder cancer drug, "a major value driver" given its formal clinical testing has begun and is "advancing well.""We believe that TLD-1433 could be FDA-approved and launched by FH222 under best-base scenario, assuming that pivotal U.S. testing begins by FH219 and that one-year recurrence free survival (RFS) data are available by FH122," he said. "Our timelines for completing pivotal U.S. testing assume that all Phase Ib testing (including a ninepatient ongoing Canada-based trial for which we expect final three-month response rate in FH118) can conclude by FH119, an aggressive but achievable time horizon in our view
EXPOSURE is increasing,,, you can see it in the aggreators and newsletters. Globe and mail buy rating anaylyst upgrade,,, 90 cent target. $$$
Found quote here:
Echelon Wealth Partners analyst Douglas Loe initiated coverage of Theralase Technologies Inc. (TLT-X), a Toronto-based biotech company, with a "speculative buy" rating.
"Our valuation is based on NPV (35-per-cent discount rate) and multiples of our fiscal 2023 EBITDA/EPS forecasts, all based on value projected from future sales of Theralase's FDA/Health Canada-approved therapeutic laser therapy TLC-2000 and more substantively from the firm's lead clinical oncology asset, a ruthenium-based photodynamic therapy (PDT) called TLD-1433, for which Theralase's initial target market is expected to be BCG-refractory non-muscle invasive bladder cancer (NMIBC), for which Phase I testing is already well advanced and generating encouraging early data," he said.
Mr. Low called PDT TLD-1433, a bladder cancer drug, "a major value driver" given its formal clinical testing has begun and is "advancing well."
"We believe that TLD-1433 could be FDA-approved and launched by FH222 under best-base scenario, assuming that pivotal U.S. testing begins by FH219 and that one-year recurrence free survival (RFS) data are available by FH122," he said. "Our timelines for completing pivotal U.S. testing assume that all Phase Ib testing (including a ninepatient ongoing Canada-based trial for which we expect final three-month response rate in FH118) can conclude by FH119, an aggressive but achievable time horizon in our view."
He set a target price of 90 cents for its shares.